CLINICAL TRIALS PROFILE FOR PATADAY TWICE DAILY RELIEF
✉ Email this page to a colleague
All Clinical Trials for PATADAY TWICE DAILY RELIEF
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00534794 ↗ | Study of Two Marketed Ocular Anti-Allergy Medications in Subjects With Allergic Conjunctivitis | Completed | Merck Sharp & Dohme Corp. | Phase 4 | 2007-10-01 | The purpose of this study is to compare the effects of two marked ocular anti-allergy medications in cat sensitive subjects with allergic conjunctivitis. |
| NCT01272089 ↗ | A Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With Allergic Conjunctivitis | Completed | Alcon Research | Phase 4 | 2011-05-01 | The purpose of this study was to evaluate subject perceptions of Olopatadine 0.2%, dosed once-daily, in subjects with allergic conjunctivitis and to record any adverse events as described by the subjects as a part of this post marketing surveillance study. |
| NCT01450176 ↗ | Comparing Patient Satisfaction With Pataday or Bepreve | Completed | McCabe Vision Center | N/A | 2011-09-01 | The purpose of this study is to compare patient satisfaction with Pataday (Olopatadine hydrochloride 0.2%) one daily (QD) and Bepreve (Bepotastine besilate ophthalmic solution 1.5%) two times a day (BID). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for PATADAY TWICE DAILY RELIEF
Condition Name
Clinical Trial Locations for PATADAY TWICE DAILY RELIEF
Trials by Country
Clinical Trial Progress for PATADAY TWICE DAILY RELIEF
Clinical Trial Phase
Clinical Trial Sponsors for PATADAY TWICE DAILY RELIEF
Sponsor Name
